ID
13564
Beschrijving
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00081822
Link
https://clinicaltrials.gov/show/NCT00081822
Trefwoorden
Versies (1)
- 16-02-16 16-02-16 -
Houder van rechten
CC BY-NC 3.0
Geüploaded op
16 februari 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Acute Myeloid Leukemia NCT00081822
Eligibility Acute Myeloid Leukemia NCT00081822
- StudyEvent: Eligibility
Beschrijving
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschrijving
patients with pre-existing myelodysplastic syndrome, or with antecedent hematologic disorder of >3 months duration, will be excluded. those with concomitant myelodysplasia/trilineage dysplasia noted at the time of diagnosis of aml will be eligible 74
Datatype
boolean
Alias
- UMLS CUI [1]
- C3463824
- UMLS CUI [2]
- C0018939
Beschrijving
have secondary aml (aml following chemotherapy or radiation therapy).
Datatype
boolean
Alias
- UMLS CUI [1]
- C0280449
Beschrijving
have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.
Datatype
boolean
Alias
- UMLS CUI [1]
- C0009488
Beschrijving
have a psychiatric disorder(s) that would interfere with consent, study participation or follow-up.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0021430
- UMLS CUI [1,2]
- C0439801
- UMLS CUI [1,3]
- C0009488
Beschrijving
are receiving other chemotherapy or corticosteroids (unless the latter is administered at a low dose for pre-medication purposes or for the treatment of chronic conditions - e.g., rheumatoid arthritis).
Datatype
boolean
Alias
- UMLS CUI [1]
- C0392920
- UMLS CUI [2]
- C0001617
Beschrijving
have received prior treatment for leukemia. patients who have received growth factors, cytokine support, leukapheresis, hydroxyurea, or cranial irradiation will be allowed but must discontinue treatment at least 24 hours prior to beginning treatment with clofarabine. if used, hydroxyurea must be discontinued 48 hours prior to the initiation of chemotherapy.
Datatype
boolean
Alias
- UMLS CUI [1]
- C1514463
- UMLS CUI [2]
- C0018284
- UMLS CUI [3]
- C0199974
- UMLS CUI [4]
- C0023416
- UMLS CUI [5]
- C0020402
- UMLS CUI [6]
- C0079172
Beschrijving
have any other severe concurrent disease (severe coronary artery disease (nyha class >ii), significant neurological disorder, uncontrolled diabetes, etc.), which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1321605
- UMLS CUI [1,2]
- C0439801
- UMLS CUI [1,3]
- C0009488
Beschrijving
have active central nervous system involvement with leukemia.
Datatype
boolean
Alias
- UMLS CUI [1]
- C1332884
Beschrijving
other malignancy within the past year, with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin
Datatype
boolean
Alias
- UMLS CUI [1]
- C0006826
Similar models
Eligibility Acute Myeloid Leukemia NCT00081822
- StudyEvent: Eligibility
C0023487 (UMLS CUI [2])
C3688712 (UMLS CUI [3])
C1515708 (UMLS CUI [4])
C2825131 (UMLS CUI [5])
C0032961 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C0018939 (UMLS CUI [2])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0001617 (UMLS CUI [2])
C0018284 (UMLS CUI [2])
C0199974 (UMLS CUI [3])
C0023416 (UMLS CUI [4])
C0020402 (UMLS CUI [5])
C0079172 (UMLS CUI [6])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])